
News|Articles|February 1, 2004
Extended-release formulation of oxymorphone effective for pain relief in osteoarthritis
The opioid oxymorphone (Numorphan, Endo) delivered in a new extended-release (ER) formulation significantly improves standard measures of pain and physical function in osteoarthritis (OA) patients, researchers reported at the American College of Rheumatology 67th Annual Scientific Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
4 things to know about the Abarca/LucyRx merger
2
FDA approves Skinvive to address horizontal neck wrinkles, “tech neck”
3
Healthcare's AI push is creating a new workforce challenge
4
Hospitals facing financial headwinds can't afford to ignore the mounting threats to 340B
5
































